Efficacy, Safety and Tolerability Study of Subcutaneous C.E.R.A. in Pre-Dialysis Participants With Chronic Renal Anemia
Status:
Terminated
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
This single arm study will assess the efficacy, safety and tolerability of subcutaneous
methoxy polyethylene glycol-epoetin beta (C.E.R.A.) for maintenance of hemoglobin levels in
pre-dialysis participants with chronic renal anemia. Participants currently receiving
maintenance treatment with subcutaneous darbepoetin alfa will receive monthly subcutaneous
injections of C.E.R.A. with the starting dose of 120, 200 or 360 micrograms (mcg) derived
from the dose of darbepoetin alfa or epoetin alfa in the week preceding study start.